Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells

详细信息    查看全文

• 作者：Rong Xie ; Wen-Qiang He ; Ming Shen ; Xue-Fei Shou ; Yong-Fei Wang…
• 关键词：Pituitary adenoma ; mTOR pathway ; Cell proliferation ; Hormone secretion
• 刊名：Journal of Neuro-Oncology
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：125
• 期：1
• 页码：79-89
• 全文大小：1,662 KB
• 参考文献：1.Daly AF, Burlacu MC, Livadariu E, Beckers A (2007) The epidemiology and management of pituitary incidentalomas. Horm Res 68:195-98CrossRef PubMed
  2.Neggers SJ, van der Lely AJ (2014) Medical approach to pituitary tumors. Handb Clin Neurol 124:303-16CrossRef PubMed
  3.Samarasinghe S, Emanuele MA, Mazhari A (2014) Neurology of the pituitary. Handb Clin Neurol 120:685-01CrossRef PubMed
  4.Chanson P, Brochier S (2005) Non-functioning pituitary adenomas. J Endocrinol Invest 28:93-9PubMed
  5.Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol 63:168-75CrossRef
  6.Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455-464CrossRef PubMed
  7.Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. PNAS 96:4240-245PubMed Central CrossRef PubMed
  8.Simpson L, Parsons R (2001) PTEN: life as a tumor suppressor. Exp Cell Res 264:29-1CrossRef PubMed
  9.Zhang X, Mu X, Huang O, Xie Z, Jiang M, Geng M, Shen K (2013) Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. PLoS One 268:e72053CrossRef
  10.Zhong H, Fazenbaker C, Breen S, Chen C, Huang J, Morehouse C, Yao Y, Hollingsworth RE (2014) MEDI-573, alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas. Mol Cancer Ther 13:2662-673CrossRef PubMed
  11.Xie R, Cheng MY, Li M, Xiong X, Daadi M, Sapolsky RM, Zhao H (2013) Akt isoforms differentially protect against stroke-induced neuronal injury by regulating mTOR activities. J Cereb Blood Flow Metab 33:1875-885PubMed Central CrossRef PubMed
  12.Xie R, Wang P, Cheng MY, Sapolsky RM, Ji X, Zhao H (2014) The mTOR cell signaling pathway contributes to the protective effects of ischemic postconditioning against stroke. Stroke 45:2769-776PubMed Central CrossRef PubMed
  13.Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T, Natt F, Hall J, Lane HA, Thomas G (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120:747-59CrossRef PubMed
  14.Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Drug Discov 5:671-88CrossRef
  15.Monsalves E, Juraschka K, Tateno T, Agnihotri S, Asa S, Ezzat S, Zadeh G (2014) The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer 21:R331–R344CrossRef PubMed
  16.Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I (2009) Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16:1017-027CrossRef PubMed
  17.Ooi GT, Tawadros N, Escalona RM (2004) Pituitary cell lines and their endocrine applications. Mol Cell Endocrinol 228:1-1CrossRef PubMed
  18.Liao G, Zhou J, Wang H, Mao Z, Xiao W, Wang H, She Z, Zhu Y (2010) The cell toxicity effect of secalonic acid D on GH3 cells and the related mechanisms. Oncol Rep 23:387-95PubMed
  19.Hu Q, Chen C, Khatibi NH, Li L, Yang L, Wang K (2011) Lentivirus-mediated transfer of MMP-9 shRNA provides neuroprotection following focal ischemic brain injury in rats. Brain Res 1367:347-59CrossRef PubMed
  20.Breckpot K, Dullaers M, Bonehill A, van Meirvenne S, Heirman C, de Greef C (2003) Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med 5:654-67CrossRef PubMed
  21.Apolonia L, Waddington SN, Fernandes C, Ward NJ, Bouma G, Blundell MP (2007) Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 15:1947-954CrossRef PubMed
  22.Cheng MY, Sun G, Jin M, Zhao H, Steinberg GK, Sapolsky RM (2009) Blocking glucocorticoid and enhancing estrogenic genomic signaling protects against cerebral schemia. J Cereb Blood Flow Metab 29:130-36CrossRef PubMed
  23.Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294:1942-945CrossRef PubMed
  24.Gingras AC, Raught B, Sonenberg N (2001) Control of translation by the target of rapamycin proteins. Prog Mol Subcell Biol 27:143-74CrossRef PubMed
  25.Garcia-Morales P, Hernando E, Carrasco-Garcia E, Menendez-Gutierrez MP, Saceda M, Martinez-Lacaci I (2006) Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol Cancer Ther 5:2172-181CrossRef PubMed
  26.Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T (2005) Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymp
• 作者单位：Rong Xie (1) (2) (3)
  Wen-Qiang He (1) (2) (3)
  Ming Shen (1) (2) (3)
  Xue-Fei Shou (1) (2) (3)
  Yong-Fei Wang (1) (2) (3)
  Wei-Min Bao (1) (2) (3)
  Yao Zhao (1) (2) (3)
  
  1. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 200040, China
  2. Shanghai Medical College, Fudan University, Shanghai, 200040, China
  3. Shanghai Pituitary Tumor Center, Shanghai, 200040, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7373

文摘

There are some evidences that pituitary tumors may be sensitive to the anti-proliferative effects of mammalian target of rapamycin (mTOR) inhibitors, while the mechanism and effects remains unclear, it is necessary to find if a specific mTOR inhibition, including the blocking of both mTOR function and expression, generate any effects on pituitary adenoma cells. The object of this study was to examine if specific inhibition of mTOR induced anti-proliferative effect and decreased the GH and PRL hormones secretion in GH3 and MtT/E pituitary adenoma cells by using a kind of mTOR shRNA lentiviral vector. The in vitro experiments results showed mTOR shRNA transfection robustly reduced the GH3 and MtT/E cells viability in all durations (1- days) we performed, also specifically decreased both GH and PRL hormones external secretion in GH3 cells. Further results suggested that specific inhibition of mTOR decreased the hormones secretion through anti-proliferation effects on GH3 cells and reducing the hormones synthesis, but not through affecting the process of hormones secretion. Then we used phosphatidic acid (PA), a kind of mTOR activator, to promote the cell proliferation and GH and PRL hormones secretion in GH3 cells while the effects were blocked by mTOR shRNA transfection. In addition, we examined in vitro effects of PA treatment and mTOR shRNA gene transfection on major proteins expressed in the mTOR pathway in GH3 cells, and confirmed that PA treatment significant increased the protein levels of pmTOR, pS6 K and p4EBP1 in the scramble shRNA group, while the increase of protein levels was blocked by mTOR shRNA gene transfection. Moreover, mTOR shRNA gene transfection definitely inhibited the expression of mTOR and reduced the expression of pmTOR, pS6K and p4EBP1 in either PA or no PA treatment groups. These findings indicated that specific inhibition of mTOR pathway induced anti-proliferative effect and decreased the GH and PRL hormones secretion in cultured pituitary adenoma cells, which may be a novel promising and potential treatment modality for patients with secreting or non-secreting pituitary adenomas. Keywords Pituitary adenoma mTOR pathway Cell proliferation Hormone secretion